An insight into prodrug strategy for the treatment of Alzheimer’s disease

Bhilare, Neha V.; Marulkar, Vinayak S.; Kumar, Dileep; Chatap, Vivekanand K.; Patil, Kashmira S.; Shirote, Pramodkumar J.

doi:10.1007/s00044-022-02859-1

Cited by 15 publications

(5 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is preferable to have a ratio of at less than four. 28,29 According to the model; there was sufficient signal for separation at a ratio between 6.57 and 10.29, which indicated a significant separation. Models that have coefficients of variation (CV) less than 10% are considered reasonably reproducible.…”

Section: Resultsmentioning

confidence: 98%

A QbD Assisted Bioanalytical Method Development and Validation for Simultaneous Estimation of Montelukast and Bilastine by LC-MS Technique

Gnanasekaran,

Gandhimathi

2023

IJPQA

View full text Add to dashboard Cite

This study describes how to use internal standards (IS) under the Analytical Quality by Design (AQbD) methodology to measure montelukast and bilastine in artificial rabbit plasma. The protein precipitation method was used for sample preparation and extraction. The chromatographic analysis was performed on the processed materials. The measurement range of the calibration was between 2 to 40 ng/mL for Bilastine and 1 to 20 ng/mL for montelukast. Optimizing mobile phase composition, flow rate, and pH were used to determine peak area and retention time. A significant reduction in method variability was observed as a result of the method of experimental design during optimization, and this enhanced the stability of the technique. A validation study demonstrated linearity, accuracy, precision, selectivity, sensitivity, and stability for estimating bilastine and montelukast in rabbit plasma using the developed method. The chemical composition of the drug was not altered during tests on its stability in human plasma. Overall, the investigations showed that the established approach is straightforward, reliable, and affordable for use in regular pharmacokinetic and bioequivalence research.

show abstract

Section: Resultsmentioning

confidence: 98%

A QbD Assisted Bioanalytical Method Development and Validation for Simultaneous Estimation of Montelukast and Bilastine by LC-MS Technique

Gnanasekaran,

Gandhimathi

2023

IJPQA

View full text Add to dashboard Cite

show abstract

“…77 A study showed that antipsychotic medications with strong D2 receptor antagonism and illness duration are risk factors for EPS in Chinese patients with schizophrenia. 78 In developing countries like India, EPS is noticed more frequently in those aged 30 to 39 years (34.28%), 40 to 49 years (25.71%), 20 to 29 years (18.57%), and above 50 years (20%). EPS is more common in the 10 to 19 years age group.…”

Section: Discussionmentioning

confidence: 99%

Extrapyramidal Effects of First and Second Generation Antipsychotics: A Review

SM,

et al. 2023

IJDDT

View full text Add to dashboard Cite

Antipsychotics are essential for treating major psychiatric disorders like schizophrenia. Second-generation antipsychotics were developed to reduce the risk of extrapyramidal symptoms (EPS) caused by antipsychotic medications. While second-generation drugs have a lower risk of EPS than first-generation treatments, studies show that they can still cause EPS, with clozapine being the least risky and risperidone the most. A literature search of PubMed and Scopus databases until April 2023 found that high doses, a history of past EPS, comorbidities, and specific second-generation medications can increase the risk of EPS. The choice of a first-generation comparator also influences study findings. Although the prevalence and severity of EPS vary with antipsychotics, these medications have not met expectations in terms of tolerability. EPS is still a clinical issue, even in the era of second-generation antipsychotics. This review offers a concise overview of EPS induced by antipsychotics.

show abstract

“…When compared to Box-Behnken Design (BBD), Central Composite Design (CCD) is considered advantageous for its operation at extreme conditions (factorial points, axial points, and centre points) with minimal risks for practical concerns outweighing statistical problems in studying the relationship between multiple input variables (factors) and one or more response variables. 47,48…”

Section: Discussionmentioning

confidence: 99%

Response Surface Methodology Assisted RP-HPLC Method for the Determination of Meropenem in Human Plasma: Application to a Pharmacokinetic Study

Karthika,

Nagappan

et al. 2023

IJPQA

View full text Add to dashboard Cite

A simple, accurate and precise development of an reversed-phase high-performance liquid chromatography (RP-HPLC) method for the quantification of meropenem in human plasma samples for therapeutic drug monitoring (TDM) was developed and validated after optimization of various chromatographic parameters. The best recovery of meropenem was achieved through sample preparation based on a simple extraction method that included deproteinization and extraction with acetonitrile. The developed method reported acceptable values for selectivity, linearity, accuracy and precision, carry-over, dilution integrity and stability. The developed method was efficiently shown to be applicable to a real-time monitoring and pharmacokinetic study of meropenem in critically ill patients.

show abstract

An insight into prodrug strategy for the treatment of Alzheimer’s disease

Cited by 15 publications

References 96 publications

A QbD Assisted Bioanalytical Method Development and Validation for Simultaneous Estimation of Montelukast and Bilastine by LC-MS Technique

A QbD Assisted Bioanalytical Method Development and Validation for Simultaneous Estimation of Montelukast and Bilastine by LC-MS Technique

Extrapyramidal Effects of First and Second Generation Antipsychotics: A Review

Response Surface Methodology Assisted RP-HPLC Method for the Determination of Meropenem in Human Plasma: Application to a Pharmacokinetic Study

Contact Info

Product

Resources

About